We found that cells exhibit a broad range of nonstoichiometric m 6 A levels with cell-type specificity. At the level of isoform characterization, we discovered widespread differences in the use of tandem alternative polyadenylation (APA) sites by methylated and nonmethylated transcript isoforms of individual genes. strikingly, there is a strong bias for methylated transcripts to be coupled with proximal APA sites, resulting in shortened 3′ untranslated regions, while nonmethylated transcript isoforms tend to use distal APA sites. m 6 A-lAic-seq yields a new perspective on transcriptome complexity and links APA usage to m 6 A modifications. m 6 A is the most abundant known internal chemical modification of mRNAs and long noncoding RNAs (lncRNAs) [1] [2] [3] [4] [5] [6] . m 6 A has been implicated in all forms of RNA metabolism 2-4,7-11 . The 'writing' of m 6 A RNA modification is accomplished via the m 6 A methyltransferases METTL3 and METTL14 (refs. 7, [12] [13] [14] [15] . Furthermore, m 6 A modification is reversible or 'erased' by the FTO and ALKBH5 m 6 A demethylases and 'read' by the m 6 A-binding family of YTH-domain RNA-binding proteins (RBPs), which promote degradation and translational regulation of m 6 A-modified transcripts [8] [9] [10] [11] 16, 17 . Recent findings that METTL3 is required for efficient embryonic-stem-cell differentiation highlight the functional importance of m 6 A modification 18, 19 .
N 6 -methyladenosine (m 6 A) is a widespread, reversible chemical modification of rnA molecules, implicated in many aspects of rnA metabolism. little quantitative information exists as to either how many transcript copies of particular genes are m 6 A modified ('m 6 A levels') or the relationship of m 6 A modification(s) to alternative rnA isoforms. to deconvolute the m 6 A epitranscriptome, we developed m 6 A-level and isoform-characterization sequencing (m 6 A-lAic-seq). We found that cells exhibit a broad range of nonstoichiometric m 6 A levels with cell-type specificity. At the level of isoform characterization, we discovered widespread differences in the use of tandem alternative polyadenylation (APA) sites by methylated and nonmethylated transcript isoforms of individual genes. strikingly, there is a strong bias for methylated transcripts to be coupled with proximal APA sites, resulting in shortened 3′ untranslated regions, while nonmethylated transcript isoforms tend to use distal APA sites. m 6 A-lAic-seq yields a new perspective on transcriptome complexity and links APA usage to m 6 A modifications. m 6 A is the most abundant known internal chemical modification of mRNAs and long noncoding RNAs (lncRNAs) [1] [2] [3] [4] [5] [6] . m 6 A has been implicated in all forms of RNA metabolism [2] [3] [4] [7] [8] [9] [10] [11] . The 'writing' of m 6 A RNA modification is accomplished via the m 6 A methyltransferases METTL3 and METTL14 (refs. 7,12-15) . Furthermore, m 6 A modification is reversible or 'erased' by the FTO and ALKBH5 m 6 A demethylases and 'read' by the m 6 A-binding family of YTH-domain RNA-binding proteins (RBPs), which promote degradation and translational regulation of m 6 A-modified transcripts [8] [9] [10] [11] 16, 17 . Recent findings that METTL3 is required for efficient embryonic-stem-cell differentiation highlight the functional importance of m 6 A modification 18, 19 .
Although transcriptome-wide m 6 A location analysis by m 6 Aseq (or MeRIP-seq) has led to significant insights, methods to quantify the ratio of methylated to nonmethylated transcripts (defined here as m 6 A level) on a transcriptome-wide scale have been lacking 3, 15, 20, 21 . The proportion of transcripts methylated per gene has been measured directly for only a handful of genes, and in those instances m 6 A levels were found to be nonstoichiometric (i.e., fewer than 100% of transcript copies were methylated) 22, 23 . Genome-wide quantitative measurements of m 6 A levels are critical to understanding the proportion of m 6 A-modified versus unmodified transcripts for each gene to assess the magnitude of potential m 6 A regulatory impact. Here, we report a new method, m 6 A-LAIC-seq, which quantitatively deconvolutes methylated versus nonmethylated transcripts. Unlike m 6 A-seq, our protocol does not fragment the RNA before anti-m 6 A RNA immunoprecipitation (RIP); instead relying on sequencing intact full-length transcripts in both m 6 A-positive and m 6 A-negative fractions post-RIP. While allowing quantification of m 6 A levels, the isolation and sequencing of intact full-length RNAs also allowed us to examine differential isoform usage in methylated and nonmethylated transcripts of each gene. results m 6 A-lAic-seq In developing m 6 A-LAIC-seq (Fig. 1a) , we conducted initial experiments to establish the saturation curve, sensitivity, and specificity for anti-m 6 A RIP of full-length transcripts. The anti-m 6 A antibody became saturated at 500 ng of RNA per 1 µg of antibody (500 ng µg −1 ) under our anti-m 6 A RIP conditions, which used in vitro-synthesized GAPDH transcripts containing 100% m 6 A-modified adenosines (Fig. 1b) . We started m 6 A-LAICseq with 2 µg of 2× polyadenylated (poly(A) + ) RNA, using an anti-m 6 A antibody at 500 ng µg −1 . We employed a vast excess of antibody, as a second round of anti-m 6 A RIP on the m 6 A-negative fraction recovered no further RNA ( Supplementary Fig. 1a-c) . We also found that anti-m 6 A RIP efficiency was independent of the number of modifications per transcript ( Supplementary  Fig. 1d,e) . To examine the sensitivity of the anti-m 6 A antibody in vitro, we performed anti-m 6 A RIP experiments using in vitrosynthesized GAPDH with, on average, two random m 6 A modifications per transcript as well as unmodified GAPDH transcripts, both of which were radiolabeled with CTP32. We then mixed the 6 A antibody saturation curve in vitro (n = 2). Starting with indicated amounts of in vitro-synthesized methylated GAPDH RNA as input, an anti-m 6 A dot blot was used to identify resulting amounts of m 6 A-positive material in post-RIP eluate (m 6 A-positive) and supernatant (sup, m 6 A-negative) fractions using either anti-m6A antibody or normal rabbit serum (NRS) control. In vitro-synthesized GAPDH transcripts with 100% m 6 A modification (i.e., all adenosines are m 6 A modified) were used. (c) Semiquantitative characterization of m 6 A-RIP sensitivity in vitro (n = 2). GAPDH transcripts were synthesized as either unmodified versions (i.e., 100% regular ATP) or containing on average two m 6 ATP nucleotides per transcript (see Online Methods). Various ratios (shown as percentages) of unmodified versus m 6 A-modified GAPDH transcripts were mixed and then subjected to anti-m 6 A RNA immunoprecipitation (m 6 A RIP) using anti-m 6 A antibody or normal rabbit serum (NRS RIP). (d) m 6 A-LAIC-seq sequences intact RNAs. Read coverage around m 6 A peak centers comparing previously published H1-ESC m 6 A-seq RIP fraction (brown) with input (black), m 6 A-positive (eluate, red), and m 6 A-negative (supernatant, blue) RNA fractions from m 6 A-LAIC-seq of H1-ESC. (e) m 6 A-LAIC-seq quantifies m 6 A levels. Scatterplot comparing expected versus observed m 6 A levels of spike-ins before anti-m 6 A RIP in four independent m 6 A-LAIC-seq experiments. The spike ins were multiple unique nonmammalian RNAs generated in vitro, with each transcript harboring one or two m 6 A modifications mixed with unmodified counterparts at indicated ratios as spike-ins before anti-m 6 A RIP. The Pearson correlation coefficient and P value are indicated at top left corner. The error bars represent standard error (n = 4).
unmodified and m 6 A-modified GAPDH transcripts at varying percentages. We detected as few as one m 6 A-modified transcript mixed with 1,000 unmodified transcripts, which suggested a very high sensitivity of the anti-m 6 A RIP (Fig. 1c) .
Next, we added various spike-in controls to our starting input poly(A) + RNA to evaluate the specificity, sensitivity, and quantitation of the actual m 6 A-LAIC-seq protocol (Fig. 1a) . As intended, our protocol sequenced intact full-length RNAs with no local enrichment of m 6 A sites (Fig. 1d) . Furthermore, no reads were detected of the three nonmethylated RNA transcript spike ins in the eluate (m 6 A-positive fraction), but they were readily detected in the supernatant (m 6 A-negative fraction), confirming the high specificity. We quantified m 6 A levels per gene by the ratio of RNA abundances, (eluate)/(eluate + supernatant). RNA abundances were represented by the RNA-seq fragment counts normalized across input, eluate, and supernatant using the 96 synthetic ERCC control RNAs equally spiked in just before library construction (see Online Methods). To assess m 6 A-LAIC-seq's ability to quantify m 6 A levels or stoichiometry, we mixed a series of nonmammalian m 6 A-modified RNAs generated in vitro, each with one or two modifications, with an unmodified counterpart at ratios ranging from 0-80%. Quantitative agreement between the known stoichiometry and its m 6 A-LAIC-seq quantification was excellent (Pearson r = 0.995; P = 3.7 × 10 −5 ; Fig. 1e ). m 6 A-lAic-seq reveals the transcriptome-wide patterns of m 6 A levels in h1-esc We recently characterized the m 6 A-seq profile of the hESC line H1-ESC 18 . Here we applied m 6 A-LAIC-seq to further characterize its m 6 A epitranscriptome. On a transcriptome-wide scale, we observed a strong concordance of m 6 A levels in two biological replicates (r = 0.98, P < 2.2 × 10 −16 ; Fig. 2a) , with m 6 A levels following an almost bimodal distribution whereby most genes exhibited less than 50% methylation levels (Fig. 2b) . The analysis of the relationship between the number of m 6 A peaks and m 6 A levels revealed that the more peaks present, the higher the m 6 A levels (Supplementary Fig. 2a) . Since m 6 A RIP efficiency is independent of the number of m 6 A sites and peaks (see above paragraph; Supplementary Fig. 1d,e) , the increase in m 6 A levels with number of peaks is consistent with at least some m 6 A modifications occurring at different sites on separate transcripts, as opposed to all occurring in cis on the same transcripts. Notably, m 6 A-seq-derived peak intensities correlated only modestly with m 6 A levels (r = 0.6) ( Supplementary Fig. 2b,c) . Importantly, m 6 A levels as measured by qRT-PCR correlated strongly with m 6 A-LAIC-seq data (r = 0.96; P < 2.2 × 10 −16 , Supplementary  Fig. 2d ), crossvalidating the m 6 A-LAIC-seq approach. Table 1 ). m 6 A-level-linked biological processes and protein domains To understand potential links between biological pathways and m 6 A levels, we analyzed Gene Ontology (GO) terms. The 1,000 most highly methylated genes based on m 6 A levels were enriched in terms such as regulation of transcription (false discovery rate (FDR) = 2.9 × 10 −28 ) and regulation of RNA metabolic process (FDR = 7.5 × 10 −24 ) (Fig. 2d) . This was consistent with the observation that high m 6 A levels were enriched in transcription factor (TF) domains, the strongest being TFs containing the repressive KRAB domain (FDR = 8. m 6 A levels are inversely correlated with steady-state rnA levels and half life As m 6 A is implicated in promoting RNA degradation 8, 18, 19 , we asked how m 6 A levels were related to RNA steady-state expression levels and half-life measurements 8, 18, 19 . We found an inverse correlation between m 6 A levels and steady-state expression levels (r = −0.39; P < 2.2 × 10 −16 ; Supplementary Fig. 2f ). An inverse correlation was also identified between m 6 A levels in human embryonic stem cells (hESCs) and half-life measurements in induced pluripotent stem cells (iPSCs) (r = −0.14; P < 2.2 × 10 −16 ; Supplementary Fig. 2g ) 24 . Furthermore, long intergenic noncoding RNAs (lincRNAs) had significantly higher m 6 A levels than mRNAs or pseudogenes (P = 3.0 × 10 −16 ; two-sided Wilcoxon test; Supplementary Fig. 2h and Supplementary Table 2 ). m 6 A-lAic-seq reveals the extent of differential m 6 A levels between cell types To examine variation of m 6 A levels among cell types, we performed m 6 A-LAIC-seq on the B-cell lymphoblastoid cell line GM12878, which also exhibited highly correlated m 6 A levels in replicates (Supplementary Fig. 2i ). GM12878 cells also followed a non-Gaussian bimodal m 6 A-level distribution, but exhibited higher methylation levels than H1-ESC (P < 2.2 × 10 −16 ; two-sided Wilcoxon test; Fig. 3a and Supplementary Fig. 2j ). We found that 1,509 genes exhibited a reproducible variation in m 6 A levels of at least ±10% between cell types, but almost none showed variation larger than ±20%. Furthermore, such genes were found to largely exhibit a unidirectional increase in m 6 A levels in GM12878 as compared to H1-ESC (ratio, 1,465:44) (Fig. 3b) . qRT-PCR analyses of genes with differential m 6 A levels between cell types showed highly concordant results compared to m 6 A-LAIC-seq (Fig. 3c) .
These results imply that cell-type-specific m 6 A levels of individual genes exhibit limited bidirectional variability, at least in the two cell types under the examined conditions. However, m 6 A levels appear to follow more global shifts, perhaps representing different m 6 A methyltransferase, demethylase, and/or reader expression and activity among conditions and cell types. Indeed, we found significantly higher mRNA levels of the YTH-domain-containing RBPs in H1-ESC ( Fig. 3d) , which would be expected to lead to higher rates of m 6 A-targeted RNA degradation and thus to a global reduction of H1-ESC m 6 A levels, compared to GM12878 as observed 8 .
N 6 ,2′-O-dimethyladenosine is a low-abundance modification
In transcripts starting with an adenosine, methylation of the 2′-O and the N-6 positions can lead to a modification structurally related to m 6 A, N 6 ,2′-O-dimethyladenosine (m 6 Am), that appears to be recognized by anti-m 6 A antibodies. m 6 Am is thought to occur exclusively on first nucleotides of mRNAs, whereas m 6 A has not been found at the first nucleotide position [25] [26] [27] [28] . To evaluate the impact of m 6 Am on the quantification of m 6 A level using m 6 A-LAIC-seq, we analyzed mRNAs that were unlikely to carry m 6 Am given that they lacked m 6 A-seq peak signals within the first 200 nt of any annotated isoforms. We found very similar m 6 A-level distributions between all mRNAs and the list of mRNAs lacking m 6 Am in H1-ESC, suggesting that the presence of m 6 Am was unlikely to cause significant distortions in m 6 A-level quantification ( Supplementary Fig. 3a) . However, to our knowledge, there is no report of absolute quantitative measurement of m 6 Am level in RNA. Thus, we synthesized m 6 Am standards and used liquid chromatography−mass spectrometry spectrometry (LC-MS) ( Supplementary Fig. 3b ) to quantify m 6 Am levels in poly(A) + RNA 29 . We found that H1-ESC poly(A) + RNAs contained ~3 m 6 Am nucleotides per 10 5 nucleotides compared to ~100 m 6 A nucleotides per 10 5 nucleotides, revealing 33 times more m 6 A than m 6 Am ( Supplementary Fig. 3c ). GM12878 also exhibited low levels of m 6 Am compared to m 6 A, suggesting that in both cell types m 6 Am is unlikely to skew m 6 A-LAIC-seq level results significantly ( Supplementary Fig. 3c ). Furthermore, multiple studies showed that fewer than 20% of methylated genes harbor m 6 A peaks in their 5′ UTRs 18, 25 . Even with a liberal estimate that all of these m 6 A peaks are m 6 Am, the vast majority (>80%) of genes do not have any potential m 6 Am signal, which further suggests that the impact of m 6 Am on m 6 A-LAIC-seq is limited.
internal splicing differs in m 6 A and non-m 6 A rnA fractions The m 6 A methyltransferase METTL3 has been implicated in splicing of internal exons, although the true extent of involvement is unclear 19, 21, [30] [31] [32] . Unlike traditional m 6 A-seq, m 6 A-LAIC-seq can directly compare alternatively spliced isoforms between methylated and nonmethylated RNA. By analyzing differential splicing events between these fractions using our rMATS software 33, 34 , at our current sequencing depth we detected only a limited number of differential splicing events in internal exons, including alternative cassette exons (n = 49 in H1-ESC; n = 77 in GM12878), and retained introns (n = 21 in H1-ESC; n = 78 in GM12878). There was a significant trend for alternative cassette exons included in the m 6 A-positive fraction of H1-ESC to harbor m 6 A sites as detected by m 6 A-seq (P = 2.7 × 10 −17 ; Fisher's exact test; Supplementary Fig. 4a ,b and Supplementary Table 3) . We independently validated an example of alternativecassette-exon inclusion in the m 6 A-positive fraction by RT-PCR (Supplementary Fig. 4c ). We concluded that internal isoformspecific m 6 A targeting may allow for differential regulation of individual isoforms by m 6 A modification. m 6 A modification is associated with proximal APA usage A prevalent form of mRNA isoform regulation outside of internal splicing is 3′-UTR length variation via APA. Visual inspection of m 6 A-LAIC-seq data tracks revealed numerous examples of genes with significantly differential 3′-UTR signals in m 6 A-positive versus m 6 A-negative fractions. A systematic evaluation of APA based on m 6 A-LAIC-seq (see Online Methods) revealed many genes (H1-ESC, n = 2,512; and GM12878, n = 2,260) in which methylated transcripts significantly used the proximal rather than the distal APA site and thus harbored short 3′ UTRs, compared to their nonmethylated transcripts (FDR < 0.01) (Fig. 4a, Supplementary   Fig. 5a , and Supplementary Table 4) . By contrast, we found a much smaller number of genes (H1-ESC, n = 410; and GM12878, n = 413) in which the reverse was true (Fig. 4a, Supplementary  Fig. 5a , and Supplementary Table 4) . Furthermore, the m 6 A-seq peak signals surrounding proximal poly(A) sites suggest that for genes with preferential m 6 A modification of the shorter 3′-UTR isoform, the m 6 A sites are located upstream of the proximal poly(A) + sites and are thus shared by both the shorter and longer 3′-UTR isoforms (Fig. 4b) . Figure 4c and Supplementary  Figure 5b show examples of m 6 A-LAIC-seq results for genes with or without differential APA usage. We confirmed our findings in these examples, calculating the change in the percentage of distal polyadenylation (dPAS) usage index (DPDUI) by qRT-PCR ( Fig. 4c and Supplementary Fig. 5b ) 35 . Of note, genes in which the proximal APA usage in the m 6 A-positive fraction is greater than that in the m 6 A-negative fraction, designated P/D, m 6 A + > m 6 A − , also exhibited higher m 6 A levels than genes without differential usage (P = 1.8 × 10 −152 , two-sided Wilcoxon test; Supplementary  Fig. 5c,d) . A recent study reported that genes with longer last exons have a higher density of m 6 A peaks 36 . Consistent with this observation, we found that m 6 A levels of genes are positively correlated with maximum 3′-UTR lengths as measured in input steady-state RNA-seq data (Supplementary Fig. 5e ). Detailed analyses showed that genes with higher proximal APA usage in the m 6 A-positive fraction (P/D; m 6 A + > m 6 A − ) had significantly longer 3′ UTRs (Supplementary Fig. 5f ) and lower ratios of proximal versus distal signals (Supplementary Fig. 5g,h writers (METTL3, METTL14, and WTAP) from multiple human and mouse cell lines 14, 15, 18, 19 . We observed no or limited numbers of significant APA changes in all data sets, with a trend for increased signals of proximal poly(A) sites upon depletion of m 6 A writers (Supplementary Table 5 ). Thus, compared to thousands of differential APA usage events in methylated versus nonmethylated transcripts of the same genes, the direct effect of m 6 A on APA was considerably smaller, suggesting that it is unlikely to explain the widespread association between m 6 A and proximal APA usage revealed by m 6 A-LAIC-seq. Fig. 6a ).
We also examined APA usage upon stratification of genes based on whether their transcription start sites (TSSs) are adenosine in H1-ESC and GM12878. The TSSs were annotated based on Ensembl annotation or cap analysis gene expression (CAGE) data. We found similarly strong association of m 6 A with proximal APA usage in genes with or without A at TSSs based on TSS annotation (Supplementary Fig. 6b ). These results suggest that the association between m 6 A and proximal APA usage revealed by m 6 A-LAIC-seq is not dictated by the potential presence of m 6 Am at the starting nucleotide position.
APA of m 6 A versus non-m 6 A fractions affects regulatory elements
The 3′ UTRs of transcripts serve as post-transcriptional nexuses of regulation by miRNAs as well as RBPs 37 . To assess the consequence of differential 3′-UTR usage patterns between modified and unmodified m 6 A isoforms, we analyzed potential miRNAmRNA and RBP-mRNA interactions. To do so, we analyzed predicted miRNA target sites as well as RBP-binding motifs in the (Fig. 5a,b) . By contrast, genes with higher distal APA usage in the m 6 A-positive fraction (P/D; m 6 A + < m 6 A − ) had a higher density of m 6 A RRACU motif in the extended region (Fig. 5c) .
discussion
We envision that m 6 A-LAIC-seq complements standard m 6 A-seq identification of methylation sites and adds to our armamentarium for the study of m 6 A biology. As demonstrated in this work, the combined use of these two technologies provides new insights into the dynamic range and isoform complexity of the m 6 A epitranscriptome. Factors that determine m 6 A levels remain to be elucidated, but they may be related to a number of interacting and stochastic processes ranging from the concentration of m 6 A readers, erasers, and writers to the in vivo folding and accessibility of RNA. Future application of m 6 A-LAIC-seq to a larger number of tissue types and cellular states will help further elucidate tissue or cell-state specificity of m 6 A levels and identify the regulatory logic controlling m 6 A levels. Theoretically, RNA secondary structures might affect m 6 A-LAIC-seq results if the structures in full-length RNAs shield the m 6 A sites from being recognized by the antibody. However, this scenario is unlikely, given that previous studies have shown that m 6 A modifications occur in unstructured regions 31, 32 .
A unique application of m 6 A-LAIC-seq is to deconvolute and contrast the isoform complexity of m 6 A-methylated versus nonmethylated RNA fractions in a given cell type. We found that thousands of genes with m 6 A-modified transcripts exhibited a tendency to utilize proximal APA sites, while for hundreds of genes the converse was true. These data suggest that many genes generate at least two distinct pools of transcripts, encoding the same protein in the case of mRNAs, with differing metabolic fates based on m 6 A coupled with differential binding of miRNAs and RBPs in their UTR regions. Indeed, our findings are consistent with a potential model that the m 6 A fraction of genes that often harbor shorter 3′ UTRs turns over more rapidly, leading to the observation in the steady-state RNA population that such genes have longer 3′ UTRs. Collectively, these observations may reflect the need to fine-tune the amount of RNA or protein under different circumstances using distinct post-transcriptional mechanisms 38 . For genes with tandem APA sites in the 3′ UTR, the shorter transcript isoforms have less regulatory sites at the 3′ UTR than the longer isoforms. However, they preferentially acquire m 6 A modifications and potentially turn on m 6 A-mediated regulatory pathways. Furthermore, our results suggest that rather than m 6 A METTL3 dictating APA choice, perhaps the opposite is true. APA factors may help determine m 6 A site distribution along transcripts, consistent with the predominance of m 6 A sites in 3′ UTR or last exon, along with data linking APA factors to internal exon splicing 39 . Further studies are needed to investigate the role of the APA machinery on the installment of m 6 A along transcripts 40 .
m 6 A-LAIC-seq provides a new vantage point from which to dissect and classify the human transcriptome. For example, using m 6 A-LAIC-seq as a road map, it should now be possible to study the effects of differentially depleting m 6 A-modified versus m 6 A-unmodified transcripts for the same gene by designing UTR-segment-specific shRNA or siRNAs. Furthermore, strategies employing RNA-targeting Cas9 systems will allow the rationale design of experiments based on LAIC-seq maps to track and manipulate methylated versus nonmethylated subfractions of a transcript based on their differential UTRs 41 . In addition, our work sets the foundation for subphenotyping methylated versus nonmethylated transcripts with respect to parameters such as their three-dimensional structures, half lives, and the binding specificity of RBPs on genome-wide scales.
In summary, m 6 A-LAIC-seq has revealed a new design principle embedded in the human transcriptome based on m 6 A modifications and 3′-UTR length combinatorics. Given the increasing recognition of other RNA modifications, such as 5mC, m1A, and pseudouridylation (ψ) 42 , our results may point to an even greater heterogeneity and isoform complexity of the transcriptome as part of an RNA epitranscriptome code. online methods Antibodies. Anti-m 6 A antibody: the anti-m 6 A antibody was obtained from Synaptic Systems (cat# 202 003) m 6 A rabbit polyclonal, affinity purified. Normal rabbit serum R9133-5ML, Sigma (cat# R9133). Donkey secondary anti-rabbit antibody was obtained from Amersham (cat# NA934) (antibody dilution factor, 500 ng µg −1 ).
Cell line. The GM12878 cell line was obtained by the Coriell Institute for Medical Research (cat# GM12878). The species of origin was confirmed by nucleoside phosphorylase, glucose-6-phosphate dehydrogenase, and lactate dehydrogenase. The cell lines were genotyped based on microsatellite polymorphism assay used by Coriell Institute. The GM12878 cell line tested negative for mycoplasma contamination using the polymerase chain reaction (PCR) method developed by Applied Biosystems and the MycoSEQ Mycoplasma Detection System (4460625, Life Technologies).
The H1 embryonic stem cell line was obtained from WiCell (name: WA1, alias: H1). The cell tested negative for mycoplasma infection based on PCR method. 6 Am. The synthesis of N 6 , 2′-O-dimethyladenosine was analogous to a published procedure for the synthesis of 2′-O-methyladenosine, except for the use of N 6 -methyladenosine (Berry & Associates) as starting material 29 . Purification was performed on an Agilent 1200 series HPLC equipped with a diode array detector (DAD), fraction collector, and a Synergy Fusion RP column (4 µm particle size, 80 Å pore size, 250 mm length, and 4.6 mm inner diameter) from Phenomenex at 35 °C. The solvents consisted of 5 mM ammonium acetate buffer adjusted to pH 5.5 with acetic acid (solvent A) and acetonitrile (solvent B). The elution at a flow rate of 1 mL/min started with 90% solvent A followed by a linear gradient to 21% solvent B at 15 min. Solvent B was increased further to 50% over 5 min, followed by a decrease to 10% over 3 min. The desired fractions were dried under vacuum.
Synthesis of m

Analysis of m 6 A and m 6 Am by liquid chromatography-coupled mass spectrometric analysis (LC-MS).
Prior to mass spectrometric analysis, all RNA samples were hydrolyzed enzymatically to ribonucleosides as described previously 44 . Briefly, the digestion was carried out in 0.1 mM Tris buffer (pH 8), 5 mM MgCl 2 , 0.0375 U µL −1 benzonase, 0.17 U µL −1 alkaline phosphatase, 1 U mL −1 phosphodiesterase, 3 mM desferroxamine (antioxidant), 0.3 mM butylated hydroxytoluene (antioxidant), 0.05 µM [ 15 N 5 ]-2′-deoxyadenosine (internal standard), and 5 µM 2′-deoxyinosine (internal standard) at 37 °C for 2 h. Enzymes were then removed using a YM-10 centrifugal spin column (Millipore).
Quantitative analyses of m 6 A and m 6 Am were achieved using an Agilent 1200 HPLC coupled to an Agilent 6430 triple quadrupole mass spectrometer in positive-ion mode using dynamic multiple reaction monitoring (MRM). The ribonucleosides in the hydrolyzed RNA samples were resolved on a Phenomenex C18 HPLC column (1.7 µm particle size, 100 Å pore size, 2.1 × 150 mm; 25 °C) at 330 µL/min using a solvent system consisting of 10 mM ammonium acetate in H 2 O (A) and acetonitrile (B). The elution profile was 0% B for 3 min, 0-7% B over 20 min, then to 7-40% B over 4 min, followed by a column washing at 80% B and column equilibration. The operating parameters for the mass spectrometer were as follows: gas temperature 350 °C; gas flow 10 l/min; nebulizer 50 psi and capillary voltage 3500 V, fragmentor voltage 100 V, and collision energy 15 V. The quantification of a ribonucleoside can be achieved using mass-to-charge ratio (m/z) of the parent ribonucleoside ion and m/z of the deglycosylated product ion. The nucleosides were quantified based on the transition of the parent ribonucleoside to the deglycosylated base ion: m/z, 282.1/150.1 for m 6 A and m/z, 296.1/150.1 for m 6 Am. Absolute quantities of each m 6 A and m 6 Am were determined respectively using an external calibration curve prepared with synthetic standards for each ribonucleoside. m 6 A-level dot blots. Amersham Hybond-XL (cat# RPN303s) membrane was rehydrated in H 2 O for 3 min. The membrane was then 'sandwiched' in Bio-Dot Microfiltration Apparatus (Bio-Rad, cat# 170-6545). Each well was then filled with H 2 O and flushed by gentle suction vacuum until it appeared dry. 5 µl of H 2 O alone was then applied to the membrane in each well followed by addition of indicated amount of RNA and this was allowed to bind to the membrane by gravity. The apparatus was disassembled and the membrane was crosslinked in a UV STRATALINKER 1800 using the automatic function, and then the membrane was placed back into the apparatus. The membrane was then blocked 10 min using sterile RNase DNase free TBST + 5% milk. The m 6 A primary antibody (Anti-m 6 A, Synaptic Systems, cat# 202 003) was then added at a concentration of 1:500 at room temperature for 1 h in TBST + 5% milk. The membrane was then washed four times in PBST. The membrane was then incubated with the secondary anti-rabbit antibody (1:5,000 dilution) for 30 min in TBST + 5% milk. The membrane was washed 4 times for 5 min in TBST and exposed on an autoradiographic film using Pierce ECL Western Blotting Substrate.
cDNA synthesis for qRT-PCR analysis. First, a mix was made of 100 ng of RNA in 5 µl volume, 2 µl of random hexamers (Roche), 1 µl of dNTP Mix (10 mM each) and 5 µl of ultrapure H 2 O was first generated, heated at 65 °C for 5 min and immediately put on ice. 4 µl of 5× first-strand buffer was added along with 1 µl of 0.1 M DTT, 1 µl RNase inhibitor and 1 µl of Superscript III reverse transcriptase (Invitrogen). The 20 µl reverse transcription reaction was then incubated 5 min at room temperature, then 60 min at 50 °C then 15 min at 70 °C. The freshly synthesized cDNA was treated with 1 µl of RNase H at 37 °C for 20 min.
SYBR Green qRT-PCR.
To calculate m 6 A levels by qPCR for Figures 2d and 3c and Supplementary Figures 2d and  3e , SYBR Green quantitative real-time PCR assays were performed utilizing a spike-in synthetic control called Drosophila E (see below) for normalization. Each PCR reaction was done in a 10 µl volume made of 5 µl of master mix (SYBR GreenER qPCR SuperMix for iCycler, Invitrogen), 2.5 µl of primer mix at 1.2 µM (each) and 2.5 µl of cDNA template at 20 ng µl −1 . The PCR was carried out using a standard protocol with melting curve. The amount of target was calculated using the formula: amount of target = 2 −∆∆CT (ref. 45 ).
Calculation of DPDUI. All ∆PDUI calculations were based on the method described in Masamha et al. 35 , adopted to compare UTR length in positive and negative fractions of the m 6 A IP of npg m 6 A-LAIC-seq. The following was calculated using primer sets designed in the common part of the isoforms of a transcript (called 'common primer set') as well as in the distal part of long isoform of the same transcripts (called 'distal primer set'): ∆CT (common and distal) was normalized to an artificial spike-in transcript DrosoE (described in spike-ins controls for m 6 A-LAIC-seq). ∆∆CT = ∆CT distal − ∆CT common. ∆∆∆CT = ∆∆CT negative fraction m 6 A IP − ∆∆CT positive-fraction m 6 A IP. The increase or decrease in ∆∆∆CT was given by ±2 −∆∆CT (ref. 45) .
RNA extraction, DNase I treatment, and poly(A) + selection. Total RNA was isolated from cells according to manufacturer's instructions using TRIzol LS reagent (Ambion). Total RNA was treated using DNase I (Promega) for 20 min at 37 °C. The treated RNA was then acid-phenol-chloroform extracted and chloroform extracted. The RNA was precipitated using 300 mM final concentration of NaCl 2 spiked with 1 µl of 50 mg/ml of Ultra Pure Glycogen (Promega) and 2.5 volume of 100% ethanol at −20 °C either for 2 h or overnight. The precipitated RNA was then centrifuged using a refrigerated tabletop at maximum speed (>13,000g) at 4 °C for 20 min. The precipitated RNA was then washed with 70 °C ethanol and centrifuged at maximum speed for an additional 10 min. The final pellet was then resuspended in ultrapure H 2 O. Poly(A) + RNA selection was performed twice using Dynabeads mRNA Purification Kit (Invitrogen cat. # 610.06) according to the manufacturer's protocol. The second poly(A) + RNA selection was performed using the eluate of the first poly(A) + RNA selection as starting material according to the manufacture's instruction. The obtained poly(A) + RNA was evaluated both by NanoDrop and Bioanalyzer. For all RNA samples, the concentration, purity, and integrity of the RNA were verified using a NanoDrop and Bioanalyzer.
H1-ESC cell and GM12878 cell culture. H1 (WA01) cells were cultured in feeder-free condition using mTESR1 media (Stem Cell Technologies cat. # 05850) on 6-well plates coated with Matrigel (BD Biosciences, cat. # 354603), as described 46 . GM12878 cells were cultured on complete RPMI media (Invitrogen) supplemented with 15% FBS and 10% Pen-Strep antibiotic. m 6 A level and isoform-characterization sequencing (m 6 A-LAIC-seq). Of note for each biological replicate for m 6 A-LAICseq, we started with 150 µg of total RNA yielding approximately 3.8 µg of double poly(A)-selected RNA which was resuspended in a final volume of 50 µl using UltraPure H 2 O (Life Technologies cat# 10977-015). The 2× poly(A) + RNA was then heated at 65 °C for 5 min and immediately put on ice. 50 µl of m 6 A-DynaBeads (the m 6 A antibody, Synaptic Systems cat# 202 003, was coupled to Dynabeads using the Life Technologies coupling kit cat# 14311D) were equilibrated by washing twice for 5 min in 500 µl of m 6 ABinding Buffer (50 mM Tris-HCl, 150 mM NaCl2, 1% NP-40, 0.05% EDTA). The RNA and the spike-ins controls were then added to the equilibrated m 6 A-DynaBeads. The RNA was allowed to bind to the m 6 A-Dynabeads (in 500 µl volume of m 6 A-Dynabeads and m 6 A-Binding Buffer at room temperature while rotating (tail over head) at 7 rotations per min for 1 h). The tubes containing the samples were placed on a magnet, allowing the beads complexes to cluster for 1 min or until the solution become clear. The liquid phase was carefully collected and placed on ice as this 500 µl fraction represented the 'supernatant' of the m 6 A IP. Following the collection of the supernatant fraction, series of washes were performed using various buffers (see as follows). For all wash steps, with the exception of the elution step, the beads were washed for 3 min then placed on a magnet and the wash buffers were discarded. Following the supernatant collection, Wash step 1: the remaining fractions bound to the beads were washed twice in 500 µl of m 6 A-Binding Buffer (50 mM Tris-HCl, 150 mM NaCl 2 , 1% NP-40, 0.05% EDTA). Wash step 2: the RNAbeads complexes were washed once in 500 µl of low-salt buffer (0.25× SSPE, 0.001 M EDTA, 0.05% Tween-20, 37.5 mM NaCl). Wash step 3: the RNA-beads complexes were washed once in 500 µl of high-salt buffer (0.25× SSPE, 0.001 M EDTA, 0.05% Tween-20, 137.5 mM NaCl). Wash step 4: the RNA-beads complexes were washed twice in 500 µl of TET (T.E. + 0.05% Tween-20). Elution step: The m 6 A RNA was eluted from the beads by repeating the following four times: 125 µl of elution buffer (0.02 M DTT, 0.150 M NaCl, pH 7.5 0.05 M Tris-HCl, 0.001 M EDTA, 0.10% SDS) was added to the beads and incubated at 42 °C for 5 min. At the end of the 5 min the beads were gently placed on the magnet. The liquid phase was collected and transferred to a fresh tube as this will represent the eluate fraction containing the m 6 A 'enriched RNA' . An additional 125 µl of elution buffer was then added to the beads and the process was repeated. The liquid phase obtained at each step was added to the 'fresh tube' containing the 125 µl of eluate from the previous step so the total final eluate volume was 500 µl.
All RNA fractions were extracted as follow. 500 µl of acid phenolchloroform (acid-phenol:chloroform), pH 4.5 (with IAA, 125:24:1; Ambion) was added to the 500 µl sample. The sample was centrifuged at 4 °C at 10,000g for 7.5 min. The upper phase was carefully collected, ensuring that it did not touch the interphase, and it was transferred to a clean 1.5 ml tube. 500 ml of chloroform was added to the fresh tube, mixed by gentle manual shaking, and centrifuged at 4 °C at 10,000g for 7.5 min. The upper phase was transferred to a fresh 1.5 ml tube and NaCl 2 ethanol precipitated overnight at −20 °C in the presence of 1 µl of (20 mg/ml) Ultra Pure Glycogen. The following day the sample was centrifuged at 4 °C for 20 min at 16,000g. The pellet was then washed in 70% ethanol and centrifuged an additional 10 min at 4 °C at 16,000g. The pellet was then left to dry at room temperature for 10 min before it was resuspended in the desired volume of Ultra-Pure H 2 0 (Invitrogen cat# 10977-015). Note that only one round of anti-m 6 A RNA immunoprecipitation for m 6 A-LAIC-seq was performed given our data that under the conditions we used there was essentially 100% efficiency in pulling down m 6 A-positive transcripts ( Fig. 1 and Supplementary Fig. 1 ).
Spike-in controls for m 6 A-LAIC-seq. For each sample after doublepoly(A)-RNA selection, but before anti-m 6 A RIP, in vitrotranscribed transcripts with and without m 6 A modification were mixed into the 2× poly(A) + RNA as spike-in controls at the indicated percentage of m 6 A-modified to m 6 A-unmodified transcript, the indicated number of copies, and the indicated percentage of m 6 A in the modified transcript. For all samples these spike ins included: 80% mCHERRY (10 8 copies, 0.2% m 6 A), 60% XEF (10 8 copies, 0.2% m 6 A), 20% eGFP (10 8 copies, 0.2% m 6 A), luciferase unmodified (10 8 copies, 0% m 6 A), and Kanamycin unmodified (10 8 copies, 0% m 6 A). An additional unmodified transcript originating counts of ERCC RNAs. Because there were 92 RNAs with a variety of concentrations in ERCC mixture, the ratio of ERCC RNA fragment counts between eluate and supernatant in each replicate could be accurately calculated using these RNAs together. As shown in Supplementary Figure 7 , we used the log 2 -transformed counts of ERCC RNAs to fit a linear regression model (eluate counts as a function of supernatant counts) with coefficient of 1, and the log 2 ratio between ERCC eluate counts and supernatant counts was indicated by the residual of the regression formula. To avoid using unreliable counts, only the ERCC RNAs with at least 100 counts were used to fit the regression model.
The m 6 A levels of a specific Ensembl-annotated gene or spikein RNA before m 6 A-RIP were calculated using eluate counts (E), supernatant counts (S), and the residual of ERCC regression (R) according to the following formula: For all the analyses of m 6 A levels, we required eluate counts ≥50 or supernatant counts ≥50 in both replicates to obtain reliable m 6 A levels. To compare the m 6 A levels with m 6 A peaks, we used our previously published 18 m 6 A peaks of H1 ESC cell line. The peak intensities of genes were represented by the maximum peak intensities of the peaks in the genes, and we also required the input RPKMs of the peaks ≥5 in both replicates to obtain reliable peak intensities. Gene ontology (GO) analyses for top 1,000 highly methylated genes and bottom 1,000 weakly methylated genes were conducted using DAVID 49 ; all genes with the above required read counts for level calculation were used as background. Published half-life measurements of iPSC 24 were used to compare with m 6 A levels, and the genes with average FPKMs of the two H1 replicates <5 were removed from the analyses.
Comparison of m 6 A levels between cell lines. For all the comparisons of m 6 A levels between H1-ESC and GM12878 cell lines, we required eluate counts ≥50 or supernatant counts ≥50 in both replicates of both H1-ESC and GM12878 cell lines to obtain reliable m 6 A levels. Differentially methylated genes were determined as the genes with m 6 A-level differences between cell types of > 10% or 20%.
Splicing analyses. We used rMATS (v 3.0.8) 34 to determine the differential alternative splicing events between different libraries. Four types of alternative splicing events (skipped exon (SE), alternative 5′ splice site (A5SS), alternative 3′ splice site (A3SS), and retained intron (RI)) based on annotated Ensembl genes were tested for inclusion-level difference ≥5%, and the events with FDR < 0.05 were determined as differential alternative splicing events.
Figure 2e, to make the read coverage of supernatant and eluate reflect the real ratio of their RNA abundance, we used the raw reads coverage of eluate, but we multiplied the supernatant read coverage by 2 R (as described above, R was the residue of ERCC regression formula).
